Transplanted heart made more acceptable by daclizumab
Daclizumab has been found to reduce the risk of cellular rejection after a heart transplant// when used on top of standard immunosuppression. The drug, a humanized monoclonal antibody, is directed against the interleukin-2 receptor, thereby inhibiting T-cell proliferation. Patients who we...Renal Transplantation in Children Younger Than 6 Years Old
...us in 39%, mycophenolate in 49% and azathioprine in 51%. A steroid-free protocol was used in 17% of the patients. In the last 21 cases, basiliximab or daclizumab was added. The group found that there were 13 (32.5%) graft losses. Four of these had artery/vein thromboses, 3 chronic rejections, 3 deaths, an...Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis
- Anti-IL-2 receptor antibody significantly reduced the number of new or enlarged lesions compared to placebo; data to be submitted for presentation at upcoming medical meeting - CAMBRIDGE, Mass. and FREMONT, Calif., March 12, 2007 /PRNewswire-FirstCall/ -- Biogen Idec, Inc. and PDL BioPharma, Inc...